Core Viewpoint - Nanhua Financial (00619) has signed a memorandum of understanding with a company registered in China to establish a joint venture focused on AI-enabled biotechnology, aiming to diversify its business and tap into high-growth markets [1] Group 1: Joint Venture Details - The joint venture will focus on three main areas: enabling technology using AI for data analysis and research, scientific research on molecular mechanisms for clinical applications, and developing end products for drug pipelines and clinical applications [1] - The joint venture aims to establish an AI drug development platform, provide related technical services, develop an AI efficacy prediction platform for global beauty clients, and create disease and aging pipelines along with consumer-facing anti-aging products [1] Group 2: Strategic Expansion - The company is actively seeking strategic opportunities to expand into high-tech sectors while consolidating its existing financial business [1] - Investing in AI-enabled biotechnology is a key step in the company's diversification strategy, which is expected to mitigate existing business risks and open new revenue and profit sources [1] - The board believes that the joint venture will allow the company to enter high-growth areas such as AI pharmaceuticals, beauty technology, and anti-aging consumer markets, contributing to sustainable long-term value growth [1]
南华金融(00619)拟设立合营公司进军AI制药、美妆科技及抗衰老消费市场等高增长领域